Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

THIOTEPA for Nephroblastoma: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 6 adverse event reports in the FDA FAERS database where THIOTEPA was used for Nephroblastoma.

Most Reported Side Effects for THIOTEPA

Side Effect Reports % Deaths Hosp.
Off label use 762 11.2% 187 142
Febrile neutropenia 645 9.4% 89 144
Mucosal inflammation 616 9.0% 93 131
Cytomegalovirus infection 446 6.5% 87 48
Product use in unapproved indication 425 6.2% 86 63
Pyrexia 359 5.3% 74 147
Drug ineffective 358 5.2% 77 101
Acute graft versus host disease in skin 355 5.2% 70 51
Acute graft versus host disease 331 4.8% 98 36
Cytomegalovirus infection reactivation 325 4.8% 57 56
Infection 318 4.7% 218 7
Venoocclusive liver disease 306 4.5% 115 59
Thrombocytopenia 297 4.3% 47 65
Neutropenia 288 4.2% 79 44
Sepsis 271 4.0% 138 53

Other Indications for THIOTEPA

Bone marrow conditioning regimen (1,551) Allogenic stem cell transplantation (1,476) Stem cell transplant (799) Central nervous system lymphoma (396) Diffuse large b-cell lymphoma (335) Autologous haematopoietic stem cell transplant (275) Product used for unknown indication (258) Prophylaxis against transplant rejection (195) Medulloblastoma (184) Chemotherapy (181)

Other Drugs Used for Nephroblastoma

VINCRISTINE (375) DOXORUBICIN (345) ETOPOSIDE (286) DACTINOMYCIN (278) CARBOPLATIN (228) CYCLOPHOSPHAMIDE (217) IRINOTECAN (104) IFOSFAMIDE (100) MELPHALAN (36) TOPOTECAN\TOPOTECAN (28)

Related Pages

THIOTEPA Full Profile All Nephroblastoma Drugs THIOTEPA Demographics THIOTEPA Timeline